Saturday 17 October 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.
87.57
2.63
−2.92%
Follow BNTX
BioNTech SE Sponsored ADR (BNTX) P/E ratio
BioNTech SE Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 747× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 27.1× | 653.24% |
| FY2022 | 3.6× | (30.77%) |
| FY2021 | 5.2× | (98.98%) |
| FY2020 | 510× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 747×
Ten-year median
0.0×
Current reading's percentile
50
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR | n/m |
| INSM Insmed, Inc. compare | n/m |
| INCY Incyte Corporation compare | 13.9× |
| ASND Ascendis Pharma A/S compare | 16.3× |
| EXEL Exelixis, Inc. compare | 18.8× |
| GMAB Genmab A/S Sponsored ADR compare | 29.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 39.5× |
| RPRX Royalty Pharma PLC compare | 42.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)